From: Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease
Domains PsAID | Non-MDA | MDA | VLDA | p* |
---|---|---|---|---|
Median (P25-P75) |
Median (P25-P75) |
Median (P25-P75) | ||
Pains | 6 (3-8)c | 3 (1-5)b | 0 (0-0.5)a | < 0.001 |
Fatigue/Tiredness | 5 (3-7.8)b | 2 (1.5-4.5)a | 0 (0-1.5)a | < 0.001 |
Skin Problems | 4 (1.3-6.8)b | 1 (0-2.5)a | 0 (0-3)a | < 0.001 |
Work and/or leisure activity | 5 (2-8)b | 2 (0-4)a | 0 (0-0)a | < 0.001 |
Physical Ability | 6 (3-8)b | 3 (1-5)a | 0.5 (0-1)a | < 0.001 |
Discomfort | 5 (3-8)b | 2 (0.5-4)a | 0 (0-0.3)a | < 0.001 |
Sleep disturbance | 3 (0.3-7)b | 1 (0-3)ab | 0 (0-0)a | < 0.001 |
Dealing with the disease | 4.5 (2-6)b | 2 (0-3)a | 0 (0-1)a | < 0.001 |
Anxiety/Fear/Uncertainty | 5 (2.3-8)b | 2 (0-4.5)a | 0 (0-0.3)a | < 0.001 |
Embarrassment and/or shame | 2 (0-5)b | 0 (0-1.5)ab | 0 (0-0)a | < 0.001 |
Social Participation | 2 (0-5.8)b | 0 (0-1.5)a | 0 (0-0)a | < 0.001 |
Depression | 2.5 (0-6)b | 1 (0-2)ab | 0 (0-0)a | < 0.001 |
Total score | 4.7 (3.0-6.4)c | 2.2 (1.4-3.6)b | 0.5 (0.2-0.9)a | < 0.001 |
Total PsAID ≤4 – n (%) | 44 (42.3)a | 18 (85.7)b | 14 (100)b | < 0.001 |